Company intelligence / Profile preview
Chongqing Precision Biotech
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
Overview
Chongqing Precision Biotech is a leading Chinese cell and gene therapy company specializing in CAR-T and CAR-NK therapies targeted at hematological malignancies and solid tumors. Its lead asset, pCAR-19B, has been accepted for New Drug Application (NDA) by China’s NMPA for pediatric ALL, with additional clinical-stage assets for lymphoma, myeloma, solid tumors, and licensed indications. The company reports 100% ORR in pediatric ALL Phase 2 and active INDs/programs for multiple solid tumor and blood cancer targets.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR-T cell therapyCAR-NK cell therapyStem cell therapyGene therapy
- Industry
- Biotech
Drug pipeline
41 assets40 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Chongqing Precision Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Precision Biotech.